MX2022000287A - Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso. - Google Patents

Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.

Info

Publication number
MX2022000287A
MX2022000287A MX2022000287A MX2022000287A MX2022000287A MX 2022000287 A MX2022000287 A MX 2022000287A MX 2022000287 A MX2022000287 A MX 2022000287A MX 2022000287 A MX2022000287 A MX 2022000287A MX 2022000287 A MX2022000287 A MX 2022000287A
Authority
MX
Mexico
Prior art keywords
pi4kiiiî
micromolecule
preparation
method therefor
inhibitor composition
Prior art date
Application number
MX2022000287A
Other languages
English (en)
Spanish (es)
Inventor
Feng Wang
Shu Yang
Fude Huang
Changping Jiao
Xiaojun Zhou
Original Assignee
Nuo Beta Pharmaceutical Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuo Beta Pharmaceutical Tech Shanghai Co Ltd filed Critical Nuo Beta Pharmaceutical Tech Shanghai Co Ltd
Publication of MX2022000287A publication Critical patent/MX2022000287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2022000287A 2019-07-05 2020-07-06 Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso. MX2022000287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019094831 2019-07-05
PCT/CN2020/100377 WO2021004422A1 (fr) 2019-07-05 2020-07-06 COMPOSITION D'INHIBITEUR DE PI4KIIIα MICROMOLÉCULAIRE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION

Publications (1)

Publication Number Publication Date
MX2022000287A true MX2022000287A (es) 2022-06-16

Family

ID=74115038

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000287A MX2022000287A (es) 2019-07-05 2020-07-06 Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.

Country Status (14)

Country Link
US (1) US20230115711A1 (fr)
EP (1) EP3995134A4 (fr)
JP (1) JP2022538505A (fr)
KR (1) KR20220071175A (fr)
CN (1) CN114555056B (fr)
AU (1) AU2020309681A1 (fr)
BR (1) BR112022000155A2 (fr)
CA (1) CA3149104A1 (fr)
CO (1) CO2022001218A2 (fr)
IL (1) IL289586A (fr)
MX (1) MX2022000287A (fr)
PE (1) PE20220942A1 (fr)
TW (1) TW202126294A (fr)
WO (1) WO2021004422A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685566A (zh) * 2020-12-31 2022-07-01 江苏挪贝肽医药科技有限公司 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法
TW202327565A (zh) * 2021-09-30 2023-07-16 中國大陸商挪貝肽醫藥科技（上海）有限公司 鹵代氧化苯砷化合物及其應用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056293A2 (fr) * 2001-07-10 2003-07-10 Whitehead Institute For Biomedical Research Jeux ordonnes de micro-echantillons de molecules de petite taille
CN101688206B (zh) * 2007-07-05 2013-05-15 诺瓦提斯公司 用于治疗病毒感染的dsRNA
WO2016172952A1 (fr) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 Application de la protéine pi4kiiiα et complexe de protéines de membrane associé dans le traitement de la maladie d'alzheimer
US20210361575A1 (en) * 2018-04-11 2021-11-25 New Mexico Tech University Research Park Corporation Lipid prodrugs for use in drug delivery

Also Published As

Publication number Publication date
AU2020309681A1 (en) 2022-02-24
PE20220942A1 (es) 2022-05-31
BR112022000155A2 (pt) 2022-04-12
IL289586A (en) 2022-03-01
EP3995134A4 (fr) 2023-07-12
JP2022538505A (ja) 2022-09-02
US20230115711A1 (en) 2023-04-13
KR20220071175A (ko) 2022-05-31
WO2021004422A1 (fr) 2021-01-14
EP3995134A1 (fr) 2022-05-11
CN114555056B (zh) 2024-01-05
CO2022001218A2 (es) 2022-05-20
CA3149104A1 (fr) 2021-01-14
TW202126294A (zh) 2021-07-16
CN114555056A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2018086591A8 (fr) Composés hétérotricyclo à substitution par pyridinamine, leur préparation et leur utilisation dans des médicaments
CR20220363A (es) Compuestos tricíclicos sustituidos
MX2023008716A (es) Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo.
MX2019001308A (es) Moduladores nmda espiro-lactam y metodos de uso de los mismos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
PH12021550958A1 (en) Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EP4249071A3 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
WO2021079196A3 (fr) Modulateurs de mettl3
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2021007247A (es) Derivados de rapamicina.
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
PH12021550406A1 (en) Fused ring derivative used as fgfr4 inhibitor
WO2017098051A3 (fr) Préparations combinées de modulateurs de pkm2 et de hmgb1
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
WO2018086589A8 (fr) Dérivés d'isoquinoléine 1,5,7-tri-substitués, leur préparation et leur utilisation dans des médicaments
MX2022004209A (es) Formas cristalinas de estado solido de un modulador selectivo de canales de potasio.
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.